Evidence map›Paper›PMID 36233501›Full record

ReviewJournal of clinical medicine2022

The IL-4/-13 Axis and Its Blocking in the Treatment of Atopic Dermatitis.

Georgia Pappa, Dimitrios Sgouros, Konstantinos Theodoropoulos, Antonios Kanelleas, Evangelia Bozi, Stamatios Gregoriou, Konstantinos Krasagakis, Alexander C Katoulis

Open access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Georgia Pappa2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0001-6932-1441
Dimitrios Sgouros2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.ORCID 0000-0003-0009-8821
Konstantinos Theodoropoulos2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Antonios Kanelleas2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Evangelia Bozi2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Stamatios Gregoriou1st Department of Dermatology and Venereology, "Andreas Suggros" Hospital, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece.ORCID 0000-0002-7585-1032
Konstantinos KrasagakisDepartment of Dermatology, University General Hospital of Heraklion, 71500 Heraklion, Greece.
Alexander C Katoulis2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
National and Kapodistrian University of Athens · GRUniversity Hospital of Heraklion · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atopic dermatitis (AD) is a common inflammatory skin disease with a complex pathophysiology, intertwining immune dysregulation, epidermal barrier dysfunction, IgE sensitization, environmental factors and genetic predisposition. It has been recently identified that interleukins -4 and -13 play crucial roles in the type-2-driven inflammation that characterizes AD, contributing to its symptomatology. Novel therapeutic approaches that target Th2 cytokines and their respective pathways have been developed, aiming to optimize the treatment of AD.

Indexed as

atopic dermatitisbiologicsinterleukin 4/13Th2 responsetreatment

Identifiers

PMID36233501
PMCPMC9570949
OpenAlexW4297201430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.